| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide novel MN/CA IX-specific antibodies, among other MN/CA IX related inventions, generated from MN/CA IX-deficient mouse, preferably monoclonal antibodies and immunoreactive fragments and recombination variants thereof. <P>SOLUTION: Subsets of the novel antibodies are antibodies to either the proteoglycan-like (PG) domain or to the carbonic anhydrase (CA) domain of MN/CA IX, and methods are provided whereby antibodies can be prepared to the other MN/CA IX domains. Such novel MN/CA IX-specific antibodies, fragments and variants are diagnostically, prognostically and therapeutically useful for cancer and precancer. Particularly preferred are the novel monoclonal antibodies, fragments and variants that are specific to the non-immunodominant epitopes of MN/CA IX, which antibodies are, among other uses, useful for detecting soluble MN/CA IX (s-CA IX) in body fluids, alone but preferably in combination with antibodies specific to the immunodominant epitopes of MN/CA IX, for example, in a sandwich assay. <P>COPYRIGHT: (C)2009,JPO&INPIT |
